Standardized assays to monitor drug sensitivity in hematologic cancers.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
13
07
2023
accepted:
13
11
2023
revised:
21
10
2023
medline:
2
12
2023
pubmed:
2
12
2023
entrez:
1
12
2023
Statut:
epublish
Résumé
The principle of drug sensitivity testing is to expose cancer cells to a library of different drugs and measure its effects on cell viability. Recent technological advances, continuous approval of targeted therapies, and improved cell culture protocols have enhanced the precision and clinical relevance of such screens. Indeed, drug sensitivity testing has proven diagnostically valuable for patients with advanced hematologic cancers. However, different cell types behave differently in culture and therefore require optimized drug screening protocols to ensure that their ex vivo drug sensitivity accurately reflects in vivo drug responses. For example, primary chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) cells require unique microenvironmental stimuli to survive in culture, while this is less the case for acute myeloid leukemia (AML) cells. Here, we present our optimized and validated protocols for culturing and drug screening of primary cells from AML, CLL, and MM patients, and a generic protocol for cell line models. We also discuss drug library designs, reproducibility, and quality controls. We envision that these protocols may serve as community guidelines for the use and interpretation of assays to monitor drug sensitivity in hematologic cancers and thus contribute to standardization. The read-outs may provide insight into tumor biology, identify or confirm treatment resistance and sensitivity in real time, and ultimately guide clinical decision-making.
Identifiants
pubmed: 38040674
doi: 10.1038/s41420-023-01722-5
pii: 10.1038/s41420-023-01722-5
pmc: PMC10692209
doi:
Types de publication
Journal Article
Langues
eng
Pagination
435Informations de copyright
© 2023. The Author(s).
Références
Front Oncol. 2022 Nov 29;12:1040730
pubmed: 36523963
J Clin Invest. 2018 Jan 2;128(1):427-445
pubmed: 29227286
Cancer Discov. 2022 Feb;12(2):388-401
pubmed: 34789538
J Vis Exp. 2018 Oct 4;(140):
pubmed: 30346411
Blood. 1995 Feb 15;85(4):997-1005
pubmed: 7849321
Front Oncol. 2023 Mar 21;13:1146486
pubmed: 37035166
Pharm Stat. 2011 Mar-Apr;10(2):128-34
pubmed: 22328315
PLoS One. 2013 Oct 11;8(10):e76215
pubmed: 24146841
J Hematol Oncol. 2016 Mar 31;9:31
pubmed: 27036514
Sci Rep. 2014 Jun 05;4:5193
pubmed: 24898935
Blood. 2017 Aug 10;130(6):789-802
pubmed: 28619982
Cancer Res. 2013 Jan 1;73(1):285-96
pubmed: 23087056
Int J Mol Sci. 2022 Oct 25;23(21):
pubmed: 36361677
Blood Cancer Discov. 2022 Nov 2;3(6):502-515
pubmed: 36125297
Cancer Cell. 2022 Aug 8;40(8):850-864.e9
pubmed: 35868306
J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
Mol Oncol. 2022 Mar;16(5):1153-1170
pubmed: 34861096
Trends Pharmacol Sci. 2022 Nov;43(11):973-985
pubmed: 36163057
Methods Mol Biol. 2022;2449:327-348
pubmed: 35507270
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563
pubmed: 28784769
N Engl J Med. 1983 Jan 20;308(3):154-5
pubmed: 6336821
Cancer Discov. 2013 Dec;3(12):1416-29
pubmed: 24056683
Sci Rep. 2018 Dec 5;8(1):17651
pubmed: 30518828
Haematologica. 2022 Aug 01;107(8):1994-1998
pubmed: 35236056
Exp Hematol. 2020 Oct;90:52-64.e11
pubmed: 32798646
Drug Deliv Transl Res. 2023 Aug;13(8):2110-2141
pubmed: 35930221
STAR Protoc. 2022 Aug 10;3(3):101601
pubmed: 35990738
Cell Rep. 2017 Mar 28;18(13):3204-3218
pubmed: 28355571
Blood Adv. 2020 Apr 28;4(8):1628-1639
pubmed: 32311014
J Biomol Screen. 2014 Apr;19(4):483-96
pubmed: 24241711
Int J Mol Sci. 2023 Feb 20;24(4):
pubmed: 36835644
Clin Cancer Res. 2022 Oct 14;28(20):4444-4455
pubmed: 35998013
Curr Treat Options Oncol. 2022 Aug;23(8):1086-1103
pubmed: 35687257
Leukemia. 2017 Oct;31(10):2114-2121
pubmed: 28232741
Leuk Lymphoma. 2003 Mar;44(3):459-64
pubmed: 12688315
Cancer Discov. 2022 Feb;12(2):372-387
pubmed: 34635570
J Immunol Methods. 2006 Jun 30;313(1-2):209-13
pubmed: 16737707
Haematologica. 2023 Jul 01;108(7):1768-1781
pubmed: 36519325
Cancer Cell. 2022 Jan 10;40(1):26-35
pubmed: 34951956
Bioinformatics. 2023 Jan 1;39(1):
pubmed: 36573326
N Engl J Med. 1978 Jun 15;298(24):1321-7
pubmed: 77475
Nat Mach Intell. 2019 Dec;1(12):568-577
pubmed: 32368721
Blood. 1973 Jan;41(1):7-15
pubmed: 4682084
Drug Discov Today. 2016 Sep;21(9):1464-1471
pubmed: 27130156
Nat Chem Biol. 2019 Mar;15(3):232-240
pubmed: 30692684
Haematologica. 2020 Mar;105(3):708-720
pubmed: 31296572
PLoS One. 2017 Nov 1;12(11):e0187440
pubmed: 29091947
Cells. 2012 Jul 25;1(3):313-24
pubmed: 24710478
Cell Death Discov. 2023 Apr 13;9(1):125
pubmed: 37055391
Expert Rev Mol Med. 2022 Oct 03;24:e39
pubmed: 36184897
Front Oncol. 2020 Dec 17;10:607608
pubmed: 33392097
Mol Oncol. 2022 Mar;16(6):1241-1258
pubmed: 35148457
Lancet Haematol. 2017 Dec;4(12):e595-e606
pubmed: 29153976
Curr Hematol Malig Rep. 2022 Dec;17(6):217-227
pubmed: 35972641
Br J Haematol. 1991 Dec;79(4):589-94
pubmed: 1772780